A Penn Medicine neurologist was awarded the 2025 John Dystel Prize for his research on immune cells and how they interact to ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Nkarta's NKX019 offers hope for autoimmune treatment. Upcoming trial data and strategic moves could fuel recovery. Read more ...

Discover Nkarta's groundbreaking cell therapy advancements, robust financials, and investment potential. Click here to read ...

ProMIS Neurosciences Inc. , a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, ...

PR Newswire SAN FRANCISCO and SUZHOU, China, March 30, 2025 SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

Mumbai: Sun Pharma Advanced Research Company Ltd. has announced submission of an Investigational New Drug (IND) application ...

Genmab A/S announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult ...

T cell engagers are an exciting area of immunotherapy that remains in the early innings of development. We believe gamma-delta T cells offer unique properties, including tissue residence, phagocytosis ...